Header Logo

Connection

AMAN U BUZDAR to Neoplasm Metastasis

Back to Details
This is a "connection" page, showing publications AMAN U BUZDAR has written about Neoplasm Metastasis.
AMAN U BUZDAR
Connection Strength
0.896
Neoplasm Metastasis
  1. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000 Apr; 58(3):185-90.
    View in: PubMed
    Score: 0.084
  2. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 2012 Jul 01; 118(13):3244-53.
    View in: PubMed
    Score: 0.047
  3. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. Lancet Oncol. 2011 Apr; 12(4):316-8.
    View in: PubMed
    Score: 0.045
  4. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104.
    View in: PubMed
    Score: 0.031
  5. Breast cancer in men. Oncology (Williston Park). 2003 Oct; 17(10):1361-4; discussion 1364, 1369-72.
    View in: PubMed
    Score: 0.027
  6. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant. 2003 May; 9(5):330-40.
    View in: PubMed
    Score: 0.026
  7. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003; 8(4):335-41.
    View in: PubMed
    Score: 0.025
  8. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
    View in: PubMed
    Score: 0.025
  9. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001 Jun; 28(3):291-304.
    View in: PubMed
    Score: 0.023
  10. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol. 2001 Apr 01; 19(7):2002-9.
    View in: PubMed
    Score: 0.022
  11. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1999; 43(6):471-8.
    View in: PubMed
    Score: 0.019
  12. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306.
    View in: PubMed
    Score: 0.018
  13. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-65-S17-68.
    View in: PubMed
    Score: 0.018
  14. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 11):S11-13-S11-19.
    View in: PubMed
    Score: 0.017
  15. Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer. 1997 Aug; 33 Suppl 7:S3-6.
    View in: PubMed
    Score: 0.017
  16. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Aug; 14(8):2197-205.
    View in: PubMed
    Score: 0.016
  17. Aromatase inhibitors in metastatic breast cancer. Semin Oncol. 1996 Aug; 23(4 Suppl 9):28-32.
    View in: PubMed
    Score: 0.016
  18. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol. 1995 Jun; 22(3 Suppl 6):101-4.
    View in: PubMed
    Score: 0.015
  19. Use of Taxol (paclitaxel) in breast cancer. Oncology. 1994 Oct; 51 Suppl 1:29-32.
    View in: PubMed
    Score: 0.014
  20. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol. 1994; 353:193-202.
    View in: PubMed
    Score: 0.014
  21. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6.
    View in: PubMed
    Score: 0.014
  22. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
    View in: PubMed
    Score: 0.013
  23. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51.
    View in: PubMed
    Score: 0.012
  24. Letrozole in second-line therapy of advanced breast cancer: more questions than answers. J Clin Oncol. 2001 Dec 01; 19(23):4353-5.
    View in: PubMed
    Score: 0.012
  25. Recent advances in the treatment of breast cancer. Am J Med Sci. 1991 May; 301(5):337-52.
    View in: PubMed
    Score: 0.011
  26. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Feb 15; 116(4):814-21.
    View in: PubMed
    Score: 0.010
  27. Elliptinium acetate in metastatic breast cancer--a phase II study. Oncology. 1990; 47(2):101-4.
    View in: PubMed
    Score: 0.010
  28. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 01; 28(1):92-8.
    View in: PubMed
    Score: 0.010
  29. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer. 1989 Mar 01; 63(5):828-35.
    View in: PubMed
    Score: 0.010
  30. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer. 1988 Nov 15; 62(10):2105-10.
    View in: PubMed
    Score: 0.009
  31. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology. 1988; 45(5):344-5.
    View in: PubMed
    Score: 0.009
  32. Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep. 1987 Dec; 71(12):1193-6.
    View in: PubMed
    Score: 0.009
  33. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7; 365(9453):60-2.
    View in: PubMed
    Score: 0.007
  34. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9.
    View in: PubMed
    Score: 0.007
  35. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5425-31.
    View in: PubMed
    Score: 0.007
  36. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984 Feb; 7(1):45-50.
    View in: PubMed
    Score: 0.007
  37. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer. 1982 Nov 01; 50(9):1708-12.
    View in: PubMed
    Score: 0.006
  38. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8.
    View in: PubMed
    Score: 0.006
  39. Breast cancer in men. Ann Intern Med. 2002 Oct 15; 137(8):678-87.
    View in: PubMed
    Score: 0.006
  40. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug; 5(4):383-7.
    View in: PubMed
    Score: 0.006
  41. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
    View in: PubMed
    Score: 0.006
  42. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001 Oct 01; 92(7):1759-68.
    View in: PubMed
    Score: 0.006
  43. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71.
    View in: PubMed
    Score: 0.006
  44. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001; 6(2):133-46.
    View in: PubMed
    Score: 0.006
  45. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
    View in: PubMed
    Score: 0.005
  46. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant. 2000 Feb; 14(1):32-41.
    View in: PubMed
    Score: 0.005
  47. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979 Oct 05; 242(14):1509-13.
    View in: PubMed
    Score: 0.005
  48. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7.
    View in: PubMed
    Score: 0.005
  49. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11.
    View in: PubMed
    Score: 0.005
  50. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat. 1999 Apr; 54(3):225-33.
    View in: PubMed
    Score: 0.005
  51. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999 Jan 01; 85(1):104-11.
    View in: PubMed
    Score: 0.005
  52. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):115-20.
    View in: PubMed
    Score: 0.005
  53. Liver scanning in patients with breast cancer. Arch Surg. 1978 Sep; 113(9):1110-1.
    View in: PubMed
    Score: 0.005
  54. Hepatic metastasis or granuloma. Ann Intern Med. 1978 Jun; 88(6):844-5.
    View in: PubMed
    Score: 0.005
  55. Patient selection in high-dose trials of breast cancer. J Clin Oncol. 1998 Mar; 16(3):1238-9.
    View in: PubMed
    Score: 0.005
  56. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1978 Feb; 41(2):392-5.
    View in: PubMed
    Score: 0.004
  57. Estrogen therapy and metastatic breast cancer. JAMA. 1977 Jun 27; 237(26):2812.
    View in: PubMed
    Score: 0.004
  58. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8.
    View in: PubMed
    Score: 0.004
  59. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94.
    View in: PubMed
    Score: 0.004
  60. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7.
    View in: PubMed
    Score: 0.004
  61. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995 Feb; 13(2):513-29.
    View in: PubMed
    Score: 0.004
  62. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994 Apr 15; 73(8):2157-67.
    View in: PubMed
    Score: 0.003
  63. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs. 1994; 12(3):235-41.
    View in: PubMed
    Score: 0.003
  64. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9.
    View in: PubMed
    Score: 0.003
  65. Carcinoma of the male breast. Ann Intern Med. 1992 Nov 01; 117(9):771-7.
    View in: PubMed
    Score: 0.003
  66. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81.
    View in: PubMed
    Score: 0.003
  67. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991 Aug; 18(3):165-70.
    View in: PubMed
    Score: 0.003
  68. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol. 1990 Nov; 8(11):1782-8.
    View in: PubMed
    Score: 0.003
  69. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989 Oct 15; 64(8):1583-5.
    View in: PubMed
    Score: 0.003
  70. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer. 1989 Sep 01; 64(5):1002-6.
    View in: PubMed
    Score: 0.003
  71. Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat. 1989 Mar; 13(2):117-21.
    View in: PubMed
    Score: 0.002
  72. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer. 1987 Dec 01; 60(11):2596-604.
    View in: PubMed
    Score: 0.002
  73. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer. 1987 Jun 15; 59(12):1992-9.
    View in: PubMed
    Score: 0.002
  74. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. Cancer Treat Rep. 1987 Apr; 71(4):411-3.
    View in: PubMed
    Score: 0.002
  75. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar; 5(3):354-64.
    View in: PubMed
    Score: 0.002
  76. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep. 1986 Nov; 70(11):1341-2.
    View in: PubMed
    Score: 0.002
  77. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63.
    View in: PubMed
    Score: 0.002
  78. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7.
    View in: PubMed
    Score: 0.002
  79. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61.
    View in: PubMed
    Score: 0.002
  80. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4.
    View in: PubMed
    Score: 0.002
  81. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer. 1985 Sep 15; 56(6):1320-4.
    View in: PubMed
    Score: 0.002
  82. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep. 1985 Sep; 69(9):1003-4.
    View in: PubMed
    Score: 0.002
  83. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6.
    View in: PubMed
    Score: 0.002
  84. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61.
    View in: PubMed
    Score: 0.002
  85. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31.
    View in: PubMed
    Score: 0.002
  86. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer. 1983 Jul 01; 52(1):180-4.
    View in: PubMed
    Score: 0.002
  87. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6.
    View in: PubMed
    Score: 0.002
  88. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72.
    View in: PubMed
    Score: 0.002
  89. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8.
    View in: PubMed
    Score: 0.002
  90. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7.
    View in: PubMed
    Score: 0.001
  91. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec; 95(6):694-7.
    View in: PubMed
    Score: 0.001
  92. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9.
    View in: PubMed
    Score: 0.001
  93. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15; 48(2):227-32.
    View in: PubMed
    Score: 0.001
  94. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 01; 47(3):554-60.
    View in: PubMed
    Score: 0.001
  95. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72.
    View in: PubMed
    Score: 0.001
  96. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep; 93(3):399-406.
    View in: PubMed
    Score: 0.001
  97. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45.
    View in: PubMed
    Score: 0.001
  98. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7.
    View in: PubMed
    Score: 0.001
  99. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol. 1979 Dec; 12(4):333-41.
    View in: PubMed
    Score: 0.001
  100. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52.
    View in: PubMed
    Score: 0.001
  101. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer. 1979 Jul; 44(1):32-4.
    View in: PubMed
    Score: 0.001
  102. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep. 1979 Apr; 63(4):539-41.
    View in: PubMed
    Score: 0.001
  103. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Apr; 43(4):1225-33.
    View in: PubMed
    Score: 0.001
  104. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer. 1979 Mar; 43(3):1112-22.
    View in: PubMed
    Score: 0.001
  105. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979 Feb; 43(2):465-71.
    View in: PubMed
    Score: 0.001
  106. Rubidazone in metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):135-6.
    View in: PubMed
    Score: 0.001
  107. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):77-83.
    View in: PubMed
    Score: 0.001
  108. Spontaneous regression of breast carcinoma. Arch Intern Med. 1978 Nov; 138(11):1734-5.
    View in: PubMed
    Score: 0.001
  109. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu?rin. Cancer Treat Rep. 1978 Nov; 62(11):1685-92.
    View in: PubMed
    Score: 0.001
  110. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep. 1978 Oct; 62(10):1565-7.
    View in: PubMed
    Score: 0.001
  111. Endobronchial metastasis from cancer of the breast. Chest. 1978 Sep; 74(3):319-20.
    View in: PubMed
    Score: 0.001
  112. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80.
    View in: PubMed
    Score: 0.001
  113. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer. 1978 Apr; 41(4):1235-9.
    View in: PubMed
    Score: 0.001
  114. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res. 1977; (62):143-50.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.